15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 12 firms covering Tango Therapeutics Inc, 10 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $24.00 to $69.00 (about 2.9x), a sign of real disagreement on valuation. The average target of $47.11 sits 77% above the current $26.65. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 8 to 10 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.33 next quarter toward $-1.52 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 ratings
Moderate Buy
Strong Buy00%
Buy1083%
Hold217%
Sell00%
Strong Sell00%
Based on 12 analysts giving stock ratings to Tango Therapeutics Inc.
As of Jul, 10 of 12 firms rate TNGX a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TNGX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.33
Range $-0.38 – $-0.26 · 11 analysts · -354% YoY
Next period, 11 analysts expect Tango Therapeutics Inc to earn $-0.33 a share (range $-0.38 – $-0.26), versus $0.13 a year earlier. Full-year consensus is $-1.29, growing to $-1.52 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 11 analysts · -100% YoY
Revenue is expected to reach $0 (range $0 – $0), -100.0% year-over-year. Full-year consensus is $0, rising to $2.9M next year.
Top analysts covering Tango Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TNGX.
#1
Michael Schmidt
Guggenheim · Rank #1
Buy
$32.00+20.1% to target
Overall win rate
55%
+ Follow
#2
Andrew Berens
Leerink Partners · Rank #167
Buy
$69.00+158.9% to target
Overall win rate
50%
+ Follow
#3
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$66.00+147.7% to target
Overall win rate
38%
+ Follow
#4
Robert Driscoll
Wedbush · Rank #313
Buy
$33.00+23.8% to target
Overall win rate
30%
+ Follow
#5
John Newman
Canaccord Genuity · Rank #340
Buy
$46.00+72.6% to target
Overall win rate
30%
+ Follow
TNGX stock forecast FAQ
What is TNGX's average 12-month price target?+
The 9 analysts with a live target average $47.11 for Tango Therapeutics Inc over the next 12 months, ranging from a $69.00 high to a $24.00 low.
Is TNGX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 12 analyst ratings, 10 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TNGX?+
The Street-high target is $69.00 (Leerink Partners), and the Street-low is $24.00 (Piper Sandler). The average of all 9 active targets is $47.11.
How many Wall Street analysts cover TNGX?+
12 analysts have an active rating on Tango Therapeutics Inc, and 9 firms carry a live 12-month price target.
Who is the most accurate analyst covering TNGX?+
Among analysts who currently cover TNGX, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #1). Their current call is Buy with a $32.00 target.
What is Tango Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.33 per share (range $-0.38 – $-0.26) across 11 analysts. Full-year EPS is projected at $-1.29, rising to $-1.52 the following year.
How much revenue is Tango Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $2.9M next year.
Have analysts been upgrading or downgrading TNGX lately?+
As of Jul, 10 of 12 firms rate TNGX a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TNGX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
